Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single Centre, Open-label Dose-escalation Study to Assess the Safety and Immunogenicity of Three Doses of 25µg or 50 µg of Meningococcal Serogroup B Outer Membrane Vesicle Vaccine MenPF-1

NCT01640652 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT01640652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01640652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single Centre, Open-label Dose-escalation Study to Assess the Safety and Immunogenicity of Three Doses of 25µg or 50 µg of Meningococcal Serogroup B Outer Membrane Vesicle Vaccine MenPF-1
Lead sponsor
University of Oxford
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2012
Completion date
May 6, 2022
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

serogroup b meningococcal disease